The Talinolol Double-Peak Phenomenon Is Likely Caused by Presystemic Processing After Uptake from Gut Lumen
暂无分享,去创建一个
Michael Zschiesche | Werner Weitschies | Christiane Modess | Werner Siegmund | W. Weitschies | S. Nagel | Thomas Giessmann | Danilo Wegner | W. Siegmund | M. Zschiesche | T. Giessmann | C. Modess | Stefan Nagel | Annika Bernsdorf | Vera Hartmann | Claudia Mrazek | D. Wegner | Claudia Mrazek | Annika Bernsdorf | V. Hartmann | Danilo Wegner
[1] A. Breckenridge,et al. Pharmacokinetics of halofantrine in man: effects of food and dose size. , 1989, British journal of clinical pharmacology.
[2] H. Lennernäs,et al. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. , 1994, British journal of clinical pharmacology.
[3] R. Oertel,et al. Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.
[4] M Zschiesche,et al. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein , 2000, Clinical pharmacology and therapeutics.
[5] H. Koepsell. Polyspecific organic cation transporters: their functions and interactions with drugs. , 2004, Trends in pharmacological sciences.
[6] Gordon L. Amidon,et al. Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[7] T. Murakami,et al. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. , 1999, The Journal of pharmacology and experimental therapeutics.
[8] B. Hirst,et al. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[9] J. Lin,et al. Pharmacokinetic and Pharmacodynamic Properties of Histamine H2-Receptor Antagonists , 1991, Clinical pharmacokinetics.
[10] Liang-Shang Gan,et al. Mechanism of Intestinal Absorption of Ranitidine and Ondansetron: Transport Across Caco-2 Cell Monolayers , 1993, Pharmaceutical Research.
[11] W. Kirch,et al. Unexpected effect of verapamil on oral bioavailability of the β‐blocker talinolol in humans , 1999 .
[12] Patrick J. Sinko,et al. Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.
[13] Yves Plusquellec,et al. A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: A double-site model for drug absorption , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[14] Honghui Zhou. Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles , 2003, Journal of clinical pharmacology.
[15] S. Mostafavi,et al. Influence of cimetidine co-administration on the pharmacokinetics of acebutolol enantiomers and its metabolite diacetolol in a rat model: the effect of gastric pH on double-peak phenomena. , 2003, International journal of pharmaceutics.
[16] E. Harrison,et al. Mechanisms involved in the intestinal digestion and absorption of dietary vitamin A. , 2001, The Journal of nutrition.
[17] H. Akaike. A new look at the statistical model identification , 1974 .
[18] Michael Zschiesche,et al. Induction of P‐glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: A new type of drug/drug interaction , 2000, Clinical pharmacology and therapeutics.
[19] K. Bleasby,et al. The organic cation transporter OCT2 mediates the uptake of β‐adrenoceptor antagonists across the apical membrane of renal LLC‐PK1 cell monolayers , 2000, British journal of pharmacology.
[20] E. Näslund. Gastric Emptying: Comparison of Scintigraphic, Polyethylene Glycol Dilution, and Paracetamol Tracer Assessment Techniques , 2000, Scandinavian journal of gastroenterology.
[21] Michael Zschiesche,et al. Carbamazepine regulates intestinal P‐glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans , 2004, Clinical pharmacology and therapeutics.
[22] U. Klotz,et al. Site-dependent small intestinal absorption of ranitidine , 2004, European Journal of Clinical Pharmacology.
[23] K. Giacomini,et al. Stereoselective Interactions of Organic Cations with the Organic Cation Transporter in OK Cells , 1993, Pharmaceutical Research.
[24] A. Schinkel,et al. Pharmacological and Physiological Functions of the Polyspecific Organic Cation Transporters: OCT1, 2, and 3 (SLC22A1-3) , 2004, Journal of Pharmacology and Experimental Therapeutics.
[25] P. Neuvonen,et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.
[26] C. Porter,et al. Intestinal lymphatic drug transport: an update. , 2001, Advanced drug delivery reviews.
[27] H. Kroemer,et al. Stereoselective disposition of talinolol in man. , 2002, Journal of pharmaceutical sciences.
[28] Gordon L. Amidon,et al. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.
[29] T. Gramatté,et al. Paracetamol absorption from different sites in the human small intestine. , 1994, British journal of clinical pharmacology.
[30] M. Paine,et al. P-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine , 2003, Pharmaceutical Research.
[31] K. Wasan. The Role of Lymphatic Transport in Enhancing Oral Protein and Peptide Drug Delivery , 2002, Drug development and industrial pharmacy.
[32] J. Satsangi,et al. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? , 2003, Gut.
[33] W. Kirch,et al. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. , 2000, International journal of clinical pharmacology and therapeutics.
[34] W. Kirch,et al. Direct demonstration of small intestinal secretion and site‐dependent absorption of the β‐blocker talinolol in humans , 1996, Clinical pharmacology and therapeutics.
[35] I. Wilding,et al. In Vivo Evaluation of Enteric-Coated Naproxen Tablets Using Gamma Scintigraphy , 1992, Pharmaceutical Research.
[36] H. Kroemer,et al. Effect of levothyroxine administration on intestinal P‐glycoprotein expression: Consequences for drug disposition * , 2002, Clinical pharmacology and therapeutics.
[37] Hans Lennernäs,et al. Evidence for an Interaction Between the β-Blocker Pafenolol and Bile Salts in the Intestinal Lumen of the Rat Leading to Dose-Dependent Oral Absorption and Double Peaks in the Plasma Concentration–Time Profile , 1993, Pharmaceutical Research.
[38] M. Parkes,et al. Mobilisation of enterocyte fat stores by oral glucose in humans , 2003, Gut.
[39] B. Terhaag,et al. The biliary elimination of the selective beta-receptor blocking drug talinolol in man. , 1989, International journal of clinical pharmacology, therapy, and toxicology.
[40] R. Oertel,et al. Disposition and bioavailability of the β1‐adrenoceptor antagonist talinolol in man , 1995, Biopharmaceutics & drug disposition.
[41] C. Beglinger,et al. Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.
[42] S. Chetyrkin. [Transport and metabolism of vitamin A]. , 2000, Ukrains'kyi biokhimichnyi zhurnal.
[43] M. J. Story,et al. Reduced bioavailability of atenolol in man : the role of bile acids , 1993 .
[44] Michael S. Roberts,et al. Enterohepatic Circulation , 2002, Clinical pharmacokinetics.
[45] Kim L. R. Brouwer,et al. The Complexities of Hepatic Drug Transport: Current Knowledge and Emerging Concepts , 2004, Pharmaceutical Research.
[46] Panos Macheras,et al. Gastrointestinal Drug Absorption: Is It Time to Consider Heterogeneity as Well as Homogeneity? , 1997, Pharmaceutical Research.
[47] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[48] P. Langguth,et al. Evidence for Intestinal Secretion as an Additional Clearance Pathway of Talinolol Enantiomers: Concentration- and Dose-dependent Absorption in Vitro and in Vivo , 1996, Pharmaceutical Research.
[49] G. Warhurst,et al. Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(−/−) Mouse Intestine , 2002, Journal of Pharmacology and Experimental Therapeutics.
[50] J. Nezu,et al. Involvement of Human Organic Anion Transporting Polypeptide OATP-B (SLC21A9) in pH-Dependent Transport across Intestinal Apical Membrane , 2003, Journal of Pharmacology and Experimental Therapeutics.
[51] K. Johnson. An Update. , 1984, Journal of food protection.
[52] W. H. Barr,et al. Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles , 1993, Journal of clinical pharmacology.
[53] P. Tso,et al. Vitamin A uptake from foods , 2003, Current opinion in lipidology.